120 related articles for article (PubMed ID: 27595283)
1. Outcomes of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory HIV-associated lymphoma.
Ramaswami R; Pria AD; Parker K; McCann S; Kanfer EJ; Nelson M; Bower M
Bone Marrow Transplant; 2016 Dec; 51(12):1609-1611. PubMed ID: 27595283
[No Abstract] [Full Text] [Related]
2. Immune recovery after autologous stem cell transplantation is not different for HIV-infected versus HIV-uninfected patients with relapsed or refractory lymphoma.
Simonelli C; Zanussi S; Pratesi C; Rupolo M; Talamini R; Caffau C; Teresa Bortolin M; Tedeschi R; Basaglia G; Mazzucato M; Manuele R; Vaccher E; Spina M; Tirelli U; Michieli M; De Paoli P
Clin Infect Dis; 2010 Jun; 50(12):1672-9. PubMed ID: 20450419
[TBL] [Abstract][Full Text] [Related]
3. Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma.
Arcaini L; Morello L; Tucci A; Rusconi C; Ladetto M; Rattotti S; Bonfichi M; Bottelli C; Gabutti C; Bernasconi P; Varettoni M; Gotti M; Troletti D; Guerrera ML; Fiaccadori V; Sciarra R; Ferretti VV; Alessandrino EP; Rossi G; Morra E
Am J Hematol; 2015 Mar; 90(3):230-4. PubMed ID: 25502635
[TBL] [Abstract][Full Text] [Related]
4. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
[TBL] [Abstract][Full Text] [Related]
5. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.
Sibon D; Morschhauser F; Resche-Rigon M; Ghez D; Dupuis J; Marçais A; Deau-Fischer B; Bouabdallah R; Sebban C; Salles G; Brice P
Haematologica; 2016 Apr; 101(4):474-81. PubMed ID: 26721893
[TBL] [Abstract][Full Text] [Related]
6. Postautologous stem cell transplantation long-term outcomes in 26 HIV-positive patients affected by relapsed/refractory lymphoma.
Zanet E; Taborelli M; Rupolo M; Durante C; Mazzucato M; Zanussi S; De Paoli P; Serraino D; Tirelli U; Lleshi A; Michieli M
AIDS; 2015 Nov; 29(17):2303-8. PubMed ID: 26418085
[TBL] [Abstract][Full Text] [Related]
7. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy.
Molina A; Krishnan AY; Nademanee A; Zabner R; Sniecinski I; Zaia J; Forman SJ
Cancer; 2000 Aug; 89(3):680-9. PubMed ID: 10931469
[TBL] [Abstract][Full Text] [Related]
8. Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Eroglu C; Kaynar L; Orhan O; Keklik M; Sahin C; Yildiz OG; Mentes S; Kurnaz F; Aslan D; Sivgin S; Soyuer S; Eser B; Cetin M; Unal A
Am J Clin Oncol; 2015 Feb; 38(1):68-73. PubMed ID: 23563207
[TBL] [Abstract][Full Text] [Related]
9. Reconstitution of HIV-1 reservoir following high-dose chemotherapy/autologous stem cell transplantation for lymphoma.
Delagreverie HM; Gerard L; Chaillon A; Roelens M; Djerroudi L; Salmona M; Larghero J; Galicier L; Simon F; Oksenhendler E; Moins-Teisserenc H; Delaugerre C
AIDS; 2019 Feb; 33(2):247-257. PubMed ID: 30325771
[TBL] [Abstract][Full Text] [Related]
10. Relapsed/refractory Burkitt lymphoma and HIV infection.
Khan A; Brahim A; Ruiz M; Nagovski N
Int J STD AIDS; 2018 Jun; 29(7):695-703. PubMed ID: 29264956
[TBL] [Abstract][Full Text] [Related]
11. Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience.
Bourcier J; Gastinne T; Leux C; Moreau A; Bossard C; Mahé B; Blin N; Dubruille V; Touzeau C; Voldoire M; Guillaume T; Peterlin P; Gallas P; Garnier A; Maisonneuve H; Moreau P; Juge-Morineau N; Jardel H; Chevallier P; Moreau P; Le Gouill S
Ann Hematol; 2016 Aug; 95(8):1287-93. PubMed ID: 27297970
[TBL] [Abstract][Full Text] [Related]
12. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT.
Akhtar S; Al-Sugair AS; Abouzied M; Alkadhi Y; Dingle M; Abdelsalam M; Soudy H; Darwish A; Eltigani A; Elhassan TA; Nabil-Ahmed M; Maghfoor I
Bone Marrow Transplant; 2013 Nov; 48(12):1530-6. PubMed ID: 23749108
[TBL] [Abstract][Full Text] [Related]
13. Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma.
Casulo C; Arcila M; Bohn OL; Teruya-Feldstein J; Maragulia J; Moskowitz CH
Leuk Res; 2013 Sep; 37(9):1178-83. PubMed ID: 23706570
[TBL] [Abstract][Full Text] [Related]
14. High-dose therapy and autologous stem cell transplantation for children with HIV-associated non-Hodgkin lymphoma.
Fluri S; Ammann R; Lüthy AR; Hirt A; Aebi C; Duppenthaler A; Leibundgut K
Pediatr Blood Cancer; 2007 Dec; 49(7):984-7. PubMed ID: 16685736
[TBL] [Abstract][Full Text] [Related]
15. Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus.
Won JH; Han SH; Bae SB; Kim CK; Lee NS; Lee KT; Park SK; Hong DS; Lee DW; Park HS
Int J Hematol; 2006 May; 83(4):328-30. PubMed ID: 16757433
[TBL] [Abstract][Full Text] [Related]
16. Y
Voegeli M; Rondeau S; Berardi Vilei S; Lerch E; Wannesson L; Pabst T; Rentschler J; Bargetzi M; Jost L; Ketterer N; Bischof Delaloye A; Ghielmini M
Hematol Oncol; 2017 Dec; 35(4):576-583. PubMed ID: 27677906
[TBL] [Abstract][Full Text] [Related]
17. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
[TBL] [Abstract][Full Text] [Related]
18. High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma.
Aurer I; Nemet D; Mitrović Z; Dujmović D; Bašić-Kinda S; Radman I; Sertić D; Šantek F; Kralik M; Dotlić S; Mazić S; Labar B
Ann Hematol; 2016 Jun; 95(7):1129-36. PubMed ID: 27103009
[TBL] [Abstract][Full Text] [Related]
19. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.
Decaudin D; Mounier N; Tilly H; Ribrag V; Ghesquières H; Bouabdallah K; Morschhauser F; Coiffier B; Le Gouill S; Bologna S; Delarue R; Huynh A; Bosly A; Brière J; Gisselbrecht C
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):212-8. PubMed ID: 21575926
[TBL] [Abstract][Full Text] [Related]
20. Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation.
Xia W; Ma CK; Reid C; Bai L; Wong K; Kerridge I; Ward C; Greenwood M
J Clin Apher; 2014 Dec; 29(6):322-30. PubMed ID: 24944079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
